Fantaguzzi, Federico
Tombolini, Beatrice
Servillo, Andrea
Zucchiatti, Ilaria
Sacconi, Riccardo
Bandello, Francesco
Querques, Giuseppe http://orcid.org/0000-0002-3292-9581
Article History
Received: 19 July 2023
Accepted: 31 August 2023
First Online: 28 September 2023
Declarations
:
: Federico Fantaguzzi, MD: has nothing to disclose; Beatrice Tombolini, MD: has nothing to disclose; Andrea Servillo, MD: has nothing to disclose; Ilaria Zucchiatti MD has nothing to disclose; Riccardo Sacconi: is a consultant for: Allergan Inc (Irvine, California,USA), Bayer Shering-Pharma (Berlin, Germany), Carl Zeiss Meditec (Dublin, USA), Novartis (Basel, Switzerland). Francesco Bandello is a consultant for Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), Zeiss (Dublin, USA). Giuseppe Querques is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Amgen (Thousand Oaks, USA), Heidelberg (Germany), KBH (Chengdu, China), LEH Pharma (London, UK), Lumithera (Poulsbo, USA), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Sandoz (Berlin, Germany), Sifi (Catania, Italy), Soof-Fidia (Albano, Italy), Zeiss (Dublin, USA).
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.